Last reviewed 2026-04-23 · How we verify

AD-209-1C

Addpharma Inc. · Phase 2 active Small molecule

AD-209-1C is a Small molecule drug developed by Addpharma Inc.. It is currently in Phase 2 development.

At a glance

Generic name	AD-209-1C
Sponsor	Addpharma Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Efficacy and Safety of AD-209 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AD-209-1C CI brief — competitive landscape report
AD-209-1C updates RSS · CI watch RSS
Addpharma Inc. portfolio CI

Frequently asked questions about AD-209-1C

What is AD-209-1C?

AD-209-1C is a Small molecule drug developed by Addpharma Inc..

Who makes AD-209-1C?

AD-209-1C is developed by Addpharma Inc. (see full Addpharma Inc. pipeline at /company/addpharma-inc).

What development phase is AD-209-1C in?

AD-209-1C is in Phase 2.

Manufacturer: Addpharma Inc. — full pipeline
Compare: AD-209-1C vs similar drugs
Pricing: AD-209-1C cost, discount & access